The low-risk group exhibited higher infiltration of anti-tumor immune cells and greater sensitivity to ICIs, potentially mediated by the AL365361.1/hsa-miR-17-5p/NLRP3 axis. NLRP3 mutation-sensitive drugs like VNLG/124, Sunitinib, and rifampicin may benefit high-risk patients. Here, NLRP3 is linked to neoplasm.